Advertisement

Topics

The Early Medication Change (EMC) Trial

2014-08-27 03:19:26 | BioPortfolio

Summary

The EMC trial investigates for the first time prospectively whether Major Depression Disorder patients with non-improvement after 14 days of antidepressive treatment with EMC are more likely to become remitters compared to patients treated according to current guidelines, i.e., with a medication change after 28 days of treatment in case of non-response.

Study Design

Allocation: Randomized, Control: Active Control, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Conditions

Depression

Intervention

Escitalopram, venlafaxine, lithium, Escitalopram, venlafaxine

Location

University Medical Center of the Johannes Gutenberg-University
Mainz
Rheiland Pfalz
Germany
55130

Status

Recruiting

Source

Johannes Gutenberg University Mainz

Results (where available)

View Results

Links

Published on BioPortfolio: 2014-08-27T03:19:26-0400

Clinical Trials [1284 Associated Clinical Trials listed on BioPortfolio]

International Study to Predict Optimised Treatment - in Depression

The aim of this study is to identify genetic, physical (brain) and psychological (cognitive) markers (or combinations of them) that predict specific response to a range of antidepressants ...

Combining Medications to Enhance Depression Outcomes

This study will compare whether a combination of antidepressant medications is better than one antidepressant medication alone when given as initial treatment for people with chronic or r...

Treatment of Adolescent Suicide Attempters (TASA)

The purpose of this study is to compare the effects of three types of treatments for depressed teenagers who have attempted suicide.

Tamoxifen in Women With Breast Cancer and in Women at High-Risk of Breast Cancer Who Are Receiving Venlafaxine, Citalopram, Escitalopram, Gabapentin, or Sertraline

RATIONALE: Studying samples of blood in the laboratory from patients receiving tamoxifen may help doctors learn more about the effects of other drugs on the level of tamoxifen in the blood...

A Proof of Concept Study of the Prevention of Mild Cognitive Impairment and Eventual Alzheimer's Disease Using F18 Flutemetamol

This is an investigator-initiated study comparing two types of FDA-approved anti-depressants, Escitalopram and Venlafaxine, to placebo, in order to determine if these medications have posi...

PubMed Articles [2917 Associated PubMed Articles listed on BioPortfolio]

Antidepressants and Hepatotoxicity: A Cohort Study among 5 Million Individuals Registered in the French National Health Insurance Database.

Hepatotoxicity may be a concern when prescribing antidepressants. Nevertheless, this risk remains poorly understood for serotonin and noradrenaline reuptake inhibitors (SNRIs: venlafaxine, milnacipran...

Acute and chronic escitalopram alter EEG gamma oscillations differently: Relevance to therapeutic effects.

Brain oscillations in the gamma frequency band of the electroencephalogram (EEG) have been implicated in several sensory and cognitive processes, and have also been associated with numerous neuropsych...

Role of venlafaxine in prevention of cyclophosphamide-induced lung toxicity and airway hyperactivity in rats.

Cyclophosphamide (CP) is a drug used in chemotherapy and management of neoplastic diseases. This study aimed to investigate the prophylactic impacts of venlafaxine against CP-induced lung toxicity in ...

Reduced clearance of venlafaxine in a combined treatment with quetiapine.

Venlafaxine and the atypical antipsychotic quetiapine are often administered concomitantly. Both drugs share several metabolic hepatic pathways. However, pharmacokinetic interactions between venlafaxi...

Escitalopram augmentation improves negative symptoms of treatment resistant schizophrenia patients - A randomized controlled trial.

Serum interleukin (IL)-6 levels in schizophrenia correlate with the severity of negative symptoms. This study aimed to explore the potential immune mechanism of SSRI augmentation in the management of ...

Medical and Biotech [MESH] Definitions

A cyclohexanol and phenylethylamine derivative that functions as a SEROTONIN AND NORADRENALINE REUPTAKE INHIBITOR (SNRI) and is used as an ANTIDEPRESSIVE AGENT.

A cyclohexanol and phenol derivative and metabolite of venlafaxine that functions as a SEROTONIN AND NORADRENALINE REUPTAKE INHIBITOR (SNRI) and is used as an ANTIDEPRESSIVE AGENT.

A lithium salt, classified as a mood-stabilizing agent. Lithium ion alters the metabolism of BIOGENIC MONOAMINES in the CENTRAL NERVOUS SYSTEM, and affects multiple neurotransmission systems.

A salt of lithium that has been used experimentally as an immunomodulator.

Inorganic compounds that contain lithium as an integral part of the molecule.

More From BioPortfolio on "The Early Medication Change (EMC) Trial"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Depression
Depression is a serious mental health condition, where sad feelings carry on for weeks or months and interfere with your life. The symptoms include feeling unhappy most of the time (but may feel a little better in the evenings), loosing interest in lif...

Pharmacy
Pharmacy is the science and technique of preparing as well as dispensing drugs and medicines. It is a health profession that links health sciences with chemical sciences and aims to ensure the safe and effective use of pharmaceutical drugs. The scope of...

Public Health
Alternative Medicine Cleft Palate Complementary & Alternative Medicine Congenital Diseases Dentistry Ear Nose & Throat Food Safety Geriatrics Healthcare Hearing Medical Devices MRSA Muscular Dyst...


Searches Linking to this Trial